You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
9 September 2014
Poxel Raises EUR10 Million from New Investors to Progress Clinical Development of Two Novel Type 2 Diabetes Therapies
16 June 2014
Poxel’s Investigational Oral Agent – Imeglimin – Shows Unique Anti-diabetic Profile in Preclinical and Clinical Studies
6 June 2014
Poxel Announces Data Presentations at American Diabetes Association (ADA) Annual Meeting in San Francisco